Table 3.

Risk of all-cause mortality, breast cancer-specific mortality, and additional breast cancer event by inflammatory status using serum CRP concentrations in breast cancer survivors in the Women's Healthy Eating and Living Study

			Model 1a			Model 2b			Model 3c
Models of association by serum CRP	No. of Events	N	HR	95% CI	Ptrend	HR	95% CI	Ptrend	HR	95% CI	Ptrend
All-cause Mortality
Inflammatory Status					<0.001			0.005			0.006
No inflammation, CRP <1 mg/L	61	981	1.00	referrent		1.00	referrent		1.00	referrent
Low, CRP 1 to 3 mg/L	66	933	1.01	0.71–1.44		0.99	0.69–1.43		0.98	0.68–1.42
Moderate, CRP >3 to <10 mg/L	73	750	1.41	0.99–2.00		1.32	0.89–1.96		1.30	0.88–1.93
Acute, CRP ≥10 mg/L	36	255	2.12	1.38–3.23		1.96	1.22–3.13		1.92	1.20–3.08
lnCRP	236	2919	1.21	1.09–1.34		1.19	1.06–1.34		1.19	1.05–1.34
Breast cancer Mortality
Inflammatory Status					0.004			0.03			0.03
No inflammation	51	981	1.00	referent		1.00	referrent		1.00	referrent
Low Inflammation	56	933	1.10	0.75–1.62		1.07	0.71–1.59		1.07	0.72–1.59
Moderate Inflammation	53	750	1.33	0.90–1.97		1.22	0.78–1.90		1.22	0.78–1.91
Acute Inflammation	28	255	2.10	1.30–3.38		1.91	1.13–3.23		1.88	1.11–3.18
lnCRP	188	2919	1.18	1.06–1.33		1.16	1.02–1.32		1.16	1.01–1.31
Additional breast cancer events
Inflammatory Status					0.01			0.02			0.03
No inflammation	126	981	1.00	referrent		1.00	referrent		1.00	referrent
Low Inflammation	126	933	1.06	0.82–1.36		1.08	0.82–1.40		1.06	0.82–1.38
Moderate Inflammation	111	750	1.12	0.86–1.45		1.14	0.85–1.53		1.12	0.83–1.50
Acute Inflammation	54	255	1.67	1.20–2.31		1.69	1.17–2.43		1.65	1.15–2.38
lnCRP	417	2919	1.12	1.04–1.21		1.14	1.04–1.24		1.13	1.03–1.24

Abbreviation: HR, hazard ratio; 95% CI, 95 percent confidence interval, CRP, C-reactive protein; BMI, body mass index

^aAdjusted for age (continuous), time since dx, disease stage, disease grade, and race-ethnicity

^bAdjusted for age (continuous), time since dx, disease stage, disease grade, race-ethnicity, and BMI (categorical)

^cAdjusted for age (continuous), time since dx, disease stage, disease grade, race-ethnicity, BMI (categorical), anti-estrogen use and estrogen receptor/progesterone receptor status